Company intelligence / Profile preview

Neurovance, Inc.

Cambridge, Massachusetts, United Statesmnilifestyle.co.za ↗

Ownership: Private
Development stage: Phase 2

Overview

Neurovance developed centanafadine (CTN/EB‑1020), a non-stimulant triple reuptake inhibitor for ADHD. In a phase 2a pilot study in adults with ADHD, the drug showed statistically significant improvement in symptoms after four weeks of treatment. The company was acquired by Otsuka Pharmaceutical Co., Ltd. in 2017 for up to $250 million contingent on milestones[1][5].

Therapeutic areas: Psychiatry
Modalities: Small molecules (triple reuptake inhibitor)
Industry: Biotech

Drug pipeline

1 asset

centanafadine

Phase 2

Indications: Attention-deficit hyperactivity disorder (ADHD)

Partnerships

No major pharma partnerships disclosed prior to acquisition; funded by multiple venture investors.

Beyond the preview

Go deeper on Neurovance, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurovance, Inc..

Explore the full profile